Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Moncef Slaoui.
Slaoui M, Mullard A.
Nat Rev Drug Discov. 2015 Jul;14(7):452-3. doi: 10.1038/nrd4669. No abstract available.
Similar articles
Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches: features and perspectives.
Uguen D, Lönngren T, Le Cam Y, Garner S, Voisin E, Incerti C, Dunoyer M, Slaoui M.
Orphanet J Rare Dis. 2014 Feb 10;9:20. doi: 10.1186/1750-1172-9-20.
Drug discovery: a jump-start for electroceuticals.
Famm K, Litt B, Tracey KJ, Boyden ES, Slaoui M.
Nature. 2013 Apr 11;496(7444):159-61. doi: 10.1038/496159a. No abstract available.
The rise and fall of rosiglitazone: reply.
Slaoui M.
Eur Heart J. 2010 May;31(10):1282-4. No abstract available.
Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
Bourne N, Bravo FJ, Francotte M, Bernstein DI, Myers MG, Slaoui M, Stanberry LR.
J Infect Dis. 2003 Feb 15;187(4):542-9. Epub 2003 Feb 7.
Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G; GlaxoSmithKline Herpes Vaccine Efficacy Study Group.
N Engl J Med. 2002 Nov 21;347(21):1652-61.
Filters: Manage Filters